Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Creative Commons License

Eskazan A. E., Keskin D.

Therapeutic advances in hematology, cilt.8, ss.237-243, 2017 (SCI-Expanded)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1177/2040620717719851
  • Dergi Adı: Therapeutic advances in hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.237-243
  • Anahtar Kelimeler: bosutinib, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, ponatinib, radotinib, tyrosine kinase inhibitor, TYROSINE KINASE INHIBITORS, CHROMOSOME-POSITIVE LEUKEMIAS, BCR-ABL, CYTOGENETIC RESPONSES, IMATINIB, INTOLERANCE, RESISTANCE, BCR-ABL1, THERAPY, DASATINIB
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet